Biopharma · FDA Approvals · Stock

NRIX Nurix Therapeutics

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase ex…

Assets on file: bexobrutideg

Start live analysis of NRIX Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for NRIX, including recently decided ones.

January 2028

Jan 2028

~ Jan 2028

NRIXNurix Therapeutics

bexobrutideg: Phase 2 trial NCT07221500 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

October 2029

Oct 2029

~ Oct 2029

NRIXNurix Therapeutics

bexobrutideg: Phase 3 trial NCT07516093 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

May 2033

~ May 2033

NRIXNurix Therapeutics

bexobrutideg: Phase 1/Phase 2 trial NCT07520006 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for NRIX, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 13, 2026

10:19 AM

NRIXNurix Therapeutics

Nurix reports updated Phase 1/1b data for bexobrutideg (NX-5948) in CLL/SLL at EHA 2026

Nurix presented updated Phase 1a/1b results for bexobrutideg showing median PFS of 22.1 months and ORR of 83% in heavily pretreated r/r CLL/SLL patients, plus 92.9% ORR in BTKi-pretreated/BCL2-naive patients. The asset was well tolerated with low discontinuation rate due to AEs. This supports ongoing registrational Phase 2/3 trials and Roche collaboration.

Topline resultsSEC 8-K Open record

Sep 17, 2026

03:22 PM

NRIXNurix Therapeutics

bexobrutideg · NCT07221500 registry update

countries: {'total_sites': 37, 'us_sites': 25} → {'total_sites': 40, 'us_sites': 27}

Trial registry changeClinicalTrials.gov

Aug 4, 2026

05:00 AM

NRIXNurix Therapeutics

Nurix: First patient enrolled in Phase 3 DAYBreak CLL-306 of bexobrutideg vs pirtobrutinib

The first patient has been enrolled in the global registrational Phase 3 DAYBreak CLL-306 trial, marking the first Phase 3 study for bexobrutideg. The randomized study will compare bexobrutideg head-to-head against pirtobrutinib in 620 patients with relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, with dual primary endpoints of ORR and PFS.

Trial registry changeCompany press release Open record